8-K: Cypherpunk Reports 2025 Results, Zcash Strategy Drives Profit

Cypherpunk Technologies Inc. reported a significant turnaround to net income in 2025, driven by a strategic pivot to privacy technology and digital asset treasury holdings, alongside progress in its biotech subsidiary.

Summary

• Achieved a net income of $4.8 million for the year ended December 31, 2025, a substantial improvement from a net loss of $67.8 million in 2024.
• The positive financial shift was primarily due to $50.4 million in unrealized gains on the fair value of ZEC treasury holdings.
• Completed a $58.88 million private placement led by Winklevoss Capital in October 2025, issuing 15,212,311 common shares and various warrants.
• Accumulated 294,743.10 ZEC in its treasury as of March 12, 2026, at an average purchase price of $335.89, representing approximately 1.78% of the total circulating Zcash supply.
• Invested $5 million in Zcash Open Development Lab (ZODL), the developer of the Zodl wallet, in March 2026.
• Leap Therapeutics subsidiary presented positive final clinical data from the DeFianCe study for sirexatamab in DKK1-high colorectal cancer patients, showing statistically significant benefits in ORR (44.0% vs 15.8%), mPFS (9.36 months vs 5.88 months), and mOS (not reached vs 9.66 months).
• Research and development expenses decreased to $25.7 million in 2025 from $57.2 million in 2024, largely due to the completion of the sirexatamab Phase 2 program and headcount reduction.
• Cash and cash equivalents stood at $14.0 million as of December 31, 2025, with digital asset treasury holdings valued at $147.4 million.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive report, reflecting a successful strategic pivot and strong initial financial results driven by digital asset gains, coupled with promising clinical data from its biotech subsidiary. The significant capital raise and strategic appointments further bolster confidence.

Positives

• Achieved a net income of $4.8 million in 2025, a significant turnaround from a $67.8 million net loss in 2024.
• Realized $50.4 million in unrealized gains on ZEC treasury holdings, demonstrating successful digital asset strategy.
• Successfully closed a $58.88 million private placement, significantly bolstering capital.
• Accumulated a substantial ZEC treasury of 294,743.10 ZEC, positioning as a major holder in the Zcash ecosystem.
• Leap Therapeutics reported strong positive clinical data for sirexatamab in DKK1-high colorectal cancer, with statistically significant improvements in ORR (44.0% vs 15.8%), mPFS (9.36 months vs 5.88 months), and mOS (not reached vs 9.66 months).
• Reduced Research and Development expenses by over 50% to $25.7 million in 2025 from $57.2 million in 2024, reflecting efficient program completion.
• Strengthened leadership and advisory board with prominent digital asset executives and industry pioneers.

Negatives

• Cash and cash equivalents decreased significantly to $14.0 million at year-end 2025 from $47.2 million at year-end 2024, despite the capital raise, indicating substantial cash outflow for digital asset purchases and operations.
• Cash used in investing activities was $97.0 million in 2025, primarily for digital asset acquisitions, which ties up significant capital in volatile assets.
• The company's profitability is heavily reliant on the volatile fair value changes of its digital asset holdings, as evidenced by the $50.4 million unrealized gain being the primary driver of net income.

Risks

• The highly volatile nature of the price of ZEC could lead to significant changes in financial statements, including unrealized losses.
• The price of the company's Common Stock may be highly correlated to the price of ZEC.
• Failure to realize the anticipated benefits of the ZEC digital asset treasury strategy or the investment in ZODL.
• Risks related to the custody of ZEC and reliance on Gemini Space Station and its affiliates for trading and custody services.
• Significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally.
• Risks relating to the treatment of crypto assets for U.S. and foreign tax purposes.
• Ability to comply with the continued listing requirements of the Nasdaq Capital Market.
• Uncertainty regarding the ability and plan to develop and commercialize sirexatamab.
• Estimates regarding capital requirements and the ability to raise additional financing to support continued biotechnology development.
• The success of other competing therapies that may become available for cancer treatment.
• Manufacturing capacity for sirexatamab.
• Ability to maintain and protect intellectual property rights related to biotechnology.

Future Outlook

The company plans to remain focused on advancing the adoption of Zcash and expanding efforts across a broad set of technologies that defend privacy. Leap Therapeutics expects to provide an update on the next steps in sirexatamab development and its registrational pathway in the coming weeks.

Management Comments

• "2025 was a transformational year. Following a $58.88 million private placement led by Winklevoss Capital, we rebranded as Cypherpunk to become a privacy technology company with a digital asset treasury strategy focused on Zcash, while advancing sirexatamab for the treatment of patients with colorectal cancer through our Leap Therapeutics subsidiary." Douglas E. Onsi, President and CEO.
• "Since we began operating as Cypherpunk in October, we have purchased 294,743.10 ZEC for our treasury and made a $5 million strategic investment in Zcash Open Development Lab (ZODL), the development team behind Zodl, the leading Zcash wallet." Douglas E. Onsi, President and CEO.
• "In the year ahead, we will remain focused on advancing the adoption of Zcash and expanding our efforts across a broad set of technologies that defend privacy." Will McEvoy, Chief Investment Officer.

Industry Context

StockSavvy.ai notes that Cypherpunk's strategic pivot aligns with a growing trend of companies integrating digital assets and privacy-focused technologies into their core business models, reflecting increasing institutional interest in the crypto space, particularly in privacy-enhancing cryptocurrencies like Zcash. The continued development of sirexatamab by Leap Therapeutics also positions the company within the competitive oncology biotech sector, where targeted therapies for specific biomarkers like DKK1 are gaining traction.

Comparison to Industry Standards

• The $58.88 million private placement led by Winklevoss Capital demonstrates significant institutional backing, comparable to early-stage funding rounds seen in prominent crypto and biotech ventures.
• Holding 1.78% of Zcash's total circulating supply positions Cypherpunk as a substantial institutional holder, similar to how MicroStrategy has accumulated Bitcoin, though Zcash's market capitalization is significantly smaller.
• The clinical trial results for sirexatamab in DKK1-high CRC patients, with an ORR of 44.0% and mOS not reached versus 9.66 months in the control arm, show promising efficacy that could be competitive with other targeted therapies in the colorectal cancer space, such as those targeting KRAS or BRAF mutations, which often report ORRs in the 20-40% range for specific patient populations.
• The investment in ZODL, a Zcash wallet developer, mirrors strategic investments by larger crypto entities like Coinbase Ventures or a16z in infrastructure and user experience tools for specific blockchain ecosystems.

Management Changes

Stakeholder Impact

• Shareholders: Significant increase in total stockholders' equity to $153.5 million, positive net income, and promising clinical trial results could increase shareholder value. Dilution from the private placement warrants is a consideration.
• Employees: Reduction in force mentioned as a reason for decreased R&D and G&A expenses, indicating potential job losses in the biotech segment.
• Customers (Zcash users): Investment in ZODL and focus on Zcash adoption aims to improve user experience and expand the Zcash ecosystem.
• Patients (Colorectal Cancer): Positive sirexatamab clinical data offers potential new treatment options for DKK1-high CRC patients.
• Creditors: Improved financial health with a net income and increased assets could enhance creditworthiness.

Next Steps

• Remain focused on advancing the adoption of Zcash.
• Expand efforts across a broad set of technologies that defend privacy.
• Leap Therapeutics to provide an update on the next steps in sirexatamab development and on the registrational pathway in the coming weeks.
• Leap Therapeutics is engaging with regulatory agencies to discuss the registrational pathway for sirexatamab.
• Leap Therapeutics is working with a leading diagnostics research laboratory to optimize the DKK1 biomarker diagnostic test.

Key Dates

Recommendation

The company's strategic pivot to privacy technology and digital assets has yielded immediate and substantial financial benefits, evidenced by the significant net income turnaround driven by unrealized gains on ZEC holdings. The successful $58.88 million capital raise provides a strong financial foundation for this new direction. Furthermore, the Leap Therapeutics subsidiary continues to deliver highly promising clinical data for sirexatamab in colorectal cancer, indicating a dual-pronged growth strategy with significant upside potential in both high-growth tech and biotech sectors. The combination of strong financial performance, strategic clarity, and positive clinical developments makes this a compelling investment opportunity.

Keywords

Cypherpunk Technologies, Zcash, CYPH, Digital Assets, Privacy Technology, Biotechnology, Sirexatamab, Colorectal Cancer, Winklevoss Capital, ZEC, ZODL, Financial Results, SEC Filing, Crypto Treasury, Oncology